Biohaven financials
$13.29+0.15%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — |
| Operating income | -$745.4M | -$885.1M | -$436.1M | -$567.9M |
| Net income | -$738.8M | -$846.4M | -$408.2M | -$570.3M |
| Net margin | — | — | — | — |
| Diluted EPS | $-6.86 | $-9.28 | $-5.73 | $-12.75 |
| EBITDA | -$735.5M | -$877.3M | -$429.1M | -$566.5M |
| Operating cash flow | -$609.4M | -$582.5M | -$331.7M | -$297.7M |
| Free cash flow | -$610.2M | -$586.5M | -$334.8M | -$338.8M |
| Diluted shares | 107.6M | 91.2M | 71.2M | 44.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|
| Cash & equivalents | $230.0M | $99.1M | $248.4M | $204.9M |
| Short-term investments | $89.2M | $386.9M | $133.4M | $260.5M |
| Total debt | $238.9M | $0.00 | $0.00 | $0.00 |
| Total assets | $451.4M | $615.1M | $513.2M | $661.8M |
| Total liabilities | $399.4M | $191.7M | $85.2M | $123.0M |
| Shareholders' equity | $52.1M | $423.4M | $428.0M | $538.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology